The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.
KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer
Open accessAbstract
The biological functions and mechanisms of oncogenic KRAS G12D (KRAS∗) in resistance to immune checkpoint blockade (ICB) therapy are not fully understood. We demonstrate that KRAS∗ represses the expression of interferon regulatory factor 2 (IRF2), which in turn directly represses CXCL3 expression. KRAS∗-mediated repression of IRF2 results in high expression of CXCL3, which binds to CXCR2 on myeloid-derived suppressor cells and promotes their migration to the tumor microenvironment. Anti-PD-1 resistance of KRAS∗-expressing tumors can be overcome by enforced IRF2 expression or by inhibition of CXCR2. Colorectal cancer (CRC) showing higher IRF2 expression exhibited increased responsiveness to anti-PD-1 therapy. The KRAS∗-IRF2-CXCL3-CXCR2 axis provides a framework for patient selection and combination therapies to enhance the effectiveness of ICB therapy in CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In colon cancer, mutant KRAS has been shown to inhibit expression of interferon regulatory factor2 (IRF2), which is required for interferon-mediated immune responses [69].”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [69]
In the citing paper
“while decreasing the expression of those that favor immune-suppressive CD11b+ myeloid cells (e.g., CXCL1-5; CCL9; Chow and Luster, 2014; Kortlever et al., 2017; Liao et al., 2019; Nagarsheth et al., 2017; Fig. 5, I and J).”
From SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling (2021) · cites this paper as Liao et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Jemal, A., Siegel, R. L., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,184
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Flagged first, then by citations
1 of the 63 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–619 of 619
Yang, X., Tao, X., Qi, W., Luo, R., Lan, T., Xie, K., Cai, Y., Gao, F., Lv, Y., Liu, C., et al. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101718
Moreno‐Viedma, V., Adachi-Fernandez, E., Krauß, D., Mohr, T. T., Blauensteiner, B., Buresch, J., Mireva, L., Kokkinogenis, E., Filipits, M., Holcmann, M., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01828-0
Ashrafizadeh, M., Nabavi, N., & Xu, Y. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i3.36
Cheng, B., Wei, C., Niu, Z., Chen, J., Long, G., Weng, Y., Liu, Q., Jiang, Y., Wang, P., Zhang, R., et al. (2026) · Advanced Science · doi:10.1002/advs.77349
“Using t-distributed stochastic neighbor embedding (t-SNE) analysis, we identified 36 distinct cell clusters and reclassified them to 10 major immune cell subgroups, including T cells, NK cells, B cells, macrophages, and other myeloid cells [ 22, 23 ] (Figure S3A–”
Xia, Z., Chen, H., Shen, Y., Lin, M., Xie, X., Shu, H., Pang, S., Liu, D., Cao, Y., & Zhang, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1945393 · Cited by 1
“KRAS mutations, common in CRC and frequently present in MSS disease, drive MDSC recruitment through the IRF2 – CXCL3 – CXCR2 axis, linking a major oncogenic driver of MSS CRC to its immunosuppressive microenvironment (58).”
Tang, X., Yang, P., Guo, X., Wei, S., Cheng, X., Li, M., Bao, Y., Nomura, S., Sun, Y., Huangfu, L., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-026-3438-4
Mutant KRAS‐m 6 A Epitranscriptome Axis Promotes Colorectal Cancer and is a Therapeutic Target
Chen, D., Huang, P., Tao, R., Ji, F., Wei, Q., Ko, L. H., Zhou, L., Chen, H., Cheung, A. H. K., Kang, W., et al. (2026) · Advanced Science · doi:10.1002/advs.77627
“Not only that, KRAS mutations mediate primary resistance to anti-EGFR treatment in CRC patients [ 6 ], and have been associated with non-response to immune checkpoint blockade (ICB) therapy [ 7, 8 ].”
Leveraging Microphysiological Systems to Facilitate Neutrophil‐Based Cancer Immunotherapy
Shao, S., Diehl, M. I., & Jones, C. N. (2026) · Advanced Science · doi:10.1002/advs.77572
“…that CXCR1/2 inhibition to block neutrophil recruitment improves the efficacy of T cell checkpoint blockade in mice [ 99, 103, 105, 106, 108, 113 ], human cell-based organ-on-a-chip models could also be leveraged to evaluate combination immunotherapies targeting neutrophils and T cells…”
Guo, Z., Zhou, W., & Zou, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1889571
Xu, Q., Li, X., Zhu, R., Wang, Z., Tuerhonga, N., Zhao, C., & Yu, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1891806
Wang, J., Tang, X., Li, Z., Qi, Q., Sun, C., Sun, W., Zhang, W., Yin, Y., Deng, Y., Ling, P., et al. (2026) · Advanced Science · doi:10.1002/advs.77976
“Tumor-derived CXCL3 binds to CXCR2 on MDSCs, such as neutrophils, promoting their migration into the tumor microenvironment [ 63 ].”
Liao, Y., Yang, X., & Du, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1998296
“CXCR2-directed recruitment and neutrophil-mediated TGF-b activation were established through different experimental approaches (22, 23).”
Wu, Y., Lv, X., Zhang, S., Chen, Y., Liu, S., Song, F., Zhao, C., Wang, G., & Wang, X. (2026) · Cancer Science · doi:10.1111/cas.70530
“For instance, Liao et al. demonstrated that in colorectal cancer (CRC), activation of the KRAS signaling pathway promotes an immunosuppressive tumor microenvironment (TME), thereby aggravating resistance to ICIs [6].”
Self-citationLi, R., Lin, Y., Guo, J., Qian, J., Wu, M., Zhang, Y., Xiao, L., Li, R., & Zhang, X. (2026) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001846
Chemokines as regulators of CAR-T cell trafficking, function, and context-dependent tumor cell death
Levchuk, K., Petukhov, A., Tursymbek, S., Seitkamal, K., Bertleuova, A., Bulanin, D., & Barlev, N. A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1963794
“In addition, myeloid-derived suppressor cells (MDSCs) and regulatory T-cells that accumulate in the lesion can restrain CAR-T cell cytotoxicity (3, 7, 8).”
InfluentialColitis-associated colorectal carcinogenesis: molecular mechanisms and therapeutic potential
Lu, Y., Wang, X., Yin, C., Wang, J., Guo, S., Wang, Z., Zhou, J., Cui, M., Cheng, X., Zhang, L., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00623-0
“Impaired GTP hydrolysis activity induces constitutive activation, which not only autonomously drives tumor cell proliferation but also boosts secretion of various chemokines such as CXCL1 and CXCL3 [204–206].”
Wang, M., Chen, J., 吴中华, Wang, Z., Zhong, Z., & Zhong, Y. (2026) · Biomarker Research · doi:10.1186/s40364-026-01011-0
“Tumor-and stroma-derived CXCL1/2/5/8 and CCL2 can engage CXCR1/2-or CCR2-dependent migration programs, promoting myeloid infiltration and limiting effector T cell access to tumor nests [194–196].”
Cancer metastasis: biological mechanisms, therapeutic bottlenecks, and emerging interventions
Ye, H., Wei, Y., He, X., & Wei, X. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01856-w
Metadata
- Authors
- Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., Tang, M., Jiang, S., Ma, X., Chen, P., Katkhuda, R., Korphaisarn, K., Chakravarti, D., Chang, A., Spring, D. J., Chang, Q., Zhang, J., Maru, D. M., Maeda, D. Y., Zebala, J. A., Kopetz, S., Wang, Y. A., & DePinho, R. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Syntrix Biosystems (United States) (US)
- Corresponding author
- Wang, Y. Alan
- DePinho, Ronald A.
- ORCID
- Liao, Wenting
- Overman, Michael J.
- Shang, Xiaoying
- Zhao, Di
- Dey, Prasenjit
- Li, Jiexi
- Wang, Guocan
- Li, Jun
- Tang, Ming
- Jiang, Shan
- Ma, Xingdi
- Chen, Peiwen
- Korphaisarn, Krittiya
- Chakravarti, Deepavali
- Chang, Andrew
- Spring, Denise J.
- Chang, Qing
- Zhang, Jianhua
- Maru, Dipen M.
- Maeda, Dean Y.
- Zebala, John A.
- Kopetz, Scott
- Wang, Y. Alan
- DePinho, Ronald A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 35
- Issue
- 4
- Pages
- 559-572.e7
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC6467776
- OpenAlex
- W2923548794
- Cited by
- 617
- References
- 63
- Citations by year
- 2026: 68 · 2025: 91 · 2024: 104 · 2023: 89 · 2022: 97 · 2021: 86 · 2020: 62 · 2019: 20
- FWCI
- 27.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (R01 CA084628, PO1 CA117969)
- MD Anderson Colorectal Cancer Moon Shot funds
- National Basic Research Program of China (2015CB554002)
- National Natural Science Foundation of China (81672886, 81773101, 81872401)
- CPRIT (RP170067)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- KRAS G12D, IRF2, CXCL3, CXCR2, colorectal cancer, immune checkpoint inhibitor resistance, anti-PD-1 therapy, myeloid-derived suppressor cells, tumor microenvironment, immunosuppression, transcriptional repression, patient selection
- MeSH terms
- Myeloid-Derived Suppressor Cells, Antineoplastic Agents, Immunological, Adult, Aged, Animals, Cell Movement, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Colorectal Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Mice, SCID, Mice, Inbred NOD, Drug Resistance, Neoplasm, Tumor Escape, Chemokines, CXC, Receptors, Interleukin-8B, Adenomatous Polyposis Coli Protein, Cell Line, Tumor, Interferon Regulatory Factor-2, Young Adult, Tumor Microenvironment, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
